{"entity":{"id":"nct03945162","kind":"trial","name":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","aka":[],"tldr":"A phase 2 trial of Ruvidar® (TLD-1433) bladder infusion and PDT in bladder & urothelial cancer, run by Theralase® Technologies Inc., now recruiting.","summary":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients is a phase 2 interventional study registered as NCT03945162 by Theralase® Technologies Inc., with 90 participants planned, started 2019-08-30 and due to reach its primary completion in 2026-12. Interventions recorded: Ruvidar® (TLD-1433) bladder infusion and PDT.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03945162","url":"https://clinicaltrials.gov/study/NCT03945162"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","non-muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03945162","phase":"2","setting":"A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Carcinoma In-Situ (\"CIS\") or Patients Who Are Intolerant to BCG Therapy (\"Study II\")","sponsor":"Theralase® Technologies Inc.","started":"2019-08-30","startedType":"actual","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03945162/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"}]}}